FluoroPharma’s Bet On Next-Gen Molecular Imaging Agents
This article was originally published in The Pink Sheet Daily
Executive Summary
Molecular imaging’s technological advances are impressive, but getting the business model right and investors on board has been hard for start ups in the field. FluoroPharma CEO Thijs Spoor believes his company, which has several cardiovascular imaging agents in clinical trials, is on the right track and ripe for partnerships.
You may also be interested in...
PET Drugs May Get Shorter Path To FDA Approval
For positron emission tomography drugs with low levels of use that are needed to diagnose rare conditions, an expanded access IND may be the best regulatory pathway.
FDA Develops Separate Set Of GMP Requirements For PET Drug Makers
FDA will require commercial manufacturers of approved positron emission tomography drugs to meet new GMP requirements by Dec. 12, 2011. This marks the first time that FDA has mandated separate GMPs for a particular type of drug product
The Pace of Development of Molecular Imaging Agents
The adoption of new in vivo molecular imaging agents may eventually follow the current path of in vitro diagnostics, which for some products is shifting from a cost-effectiveness standard for reimbursement toward an evidence-based. But the companies most likely to support the clinical trials that would establish such benefits are only slowly integrating the development of molecular agents into their core businesses. IVD - an area of acquisition interest for these companies -may be the force that transforms them into more biologically minded and innovation-driven entities, and in so doing it may bolster the development of molecular imaging agents.